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The estimated incidence of rectal neuroendocrine tumours 
(NET) is 1.04 per 100,000 people although the real incidence 
may be higher. Recent epidemiological studies report higher 
incidence of rectal NETs in Asia comparing to Europe or North 
America [1, 2]. Most NETs are asymptomatic neoplasms dia-
gnosed in screening colonoscopy, which could be one of 
the reasons for the increasing occurrence. Less than 1% of 
rectal NETs produce serotonin; this explains why there is no 
manifestation of carcinoid syndrome. In cases of NET located 
in the rectum, the size of the tumour is strictly associated with 
its behaviour. The risk of metastases increases  with the lesions’ 
diameter [3, 4]. 
The current guidelines established by the European 
(ENETS) and North American (NANETS) Neuroendocrine 
Tumor Societies show detailed treatment algorithms that 
support the decision-making process following the diagnosis. 
The most important criteria for therapy are tumour size and 
the histopathological risk factors for metastases. For well-
-differentiated rectal neuroendocrine neoplasms <1 cm, local 
endoscopic or surgical excision is recommended. Endoscopic 
resection is sufficient in most cases: conventional polypec-
tomy or endoscopic mucosal resection (EMR) for smaller 
lesions or endoscopic submucosal resection with a ligation 
device (ESMR-L), cap-assisted EMR (EMR-C) and endoscopic 
submucosal dissection (ESD) [5]. 
Rectal NETS with a tumour diameter greater than 2 cm 
show a very high frequency of lymph node metastasis (58–
76%), and therefore these tumours are indications for rectal 
resection plus lymph node dissection. Either low anterior resec-
tion with total mesorectal excision (TME) or abdominoperineal 
resection are possible treatment options (APR) [6, 7]. Moreover, 
recent studies show that the resection of the primary tumour 
may lead to the prolonged survival of patients with GI‐NETs 
associated with metastases [8].
Zubaryev et al. in the article Local excision vs. radical surgery 
in treating rectal nets considering the biology of neuroendocrine 
tumors (NETs) raised a very important subject [9]. Due to the 
lack of evidence, tumours sized 1–2 cm represent a grey area 
for prognosis and treatment. It is crucial to apply the right 
therapy for this group of patients. Choosing the right treatment 
might be a challenge in these cases. We need to determine 
when minimally invasive treatment with endoscopy or TEM 
is sufficient. We should be careful while considering radical 
surgery, particularly when there are no clear indications after 
we have performed tumour staging. Surgeons should always 
have in mind the potential risks associated with colorectal 
surgery. There is no doubt that radical surgical treatment such 
as APR is mutilating by definition. But even laparoscopic rectal 
resections may carry significant risk. The most frequent posto-
perative surgical complications after colorectal resections are 
surgical site infections, anastomotic leakages, intra-abdominal 
abscesses, ileus and bleeding. What is more, between 25 and 
80% of patients undergoing low or very low anterior resections 
suffer postoperatively.  There are a plethora of long-term post-
-operative complications including faecal urgency, frequent 
bowel movements, bowel fragmentation and incontinence, 
collectively referred to as low anterior resection syndrome 
(LARS) [10].
In order to avoid potential trauma related to surgical treat-
ment, we should consider treatments which are as minimally 
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
118
invasive as possible, while, at the same time we should also 
have oncological indications on our mind.
We should appreciate that the authors have tried to de-
termine independent factors helping clinicians to make the 
right choice of therapy to reach a satisfactory oncological 
outcome. The impact of invasion’s depth of primary NETs 
has been confirmed to be the most important factor before 
planning treatment strategy. The authors also deserve praise 
for including a large group of patients in the study. 
According to the current state of knowledge, regarding 
tumours with a diameter of 1–2 cm, the guidelines recom-
mend local resection if neither muscularis propria invasion nor 
lymph node metastasis is suspected. The reported predictors 
of lymph node metastasis for rectal NETs present the following 
characteristics: tumour diameter >1 cm, ulcerations, presence 
of vascular invasion. It therefore seems that patients with 
tumour diameters of 1 cm or smaller and muscularis propria 
invasion or without suspicion of lymph node metastasis should 
undergo local minimally invasive resection. If a histopathologi-
cal report reveals vascular/muscularis propria invasion, positive 
surgical margins, then rectal resection with TME should be 
introduced [11].
We agree with the authors’ conclusions. It is certain that 
more prospective randomised studies are required to discover 
other prognostic factors regarding rectal NETs that might have 
an influence on treatment strategies. However, they may be 
challenging to conduct due to the limited number of cases, 
the relatively large sample size and the long-term follow-up 
period needed. 
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